-- Silicon Valley investor Khosla Ventures joins esteemed group of global
     investors backing Turn 

Turn Biotechnologies, a company developing novel RNA medicines for untreatable 
age-related conditions, today announced that it has closed its latest round of 
funding. The company has the support of investors focused on identifying and 
backing enterprises that have the potential to change the world with their 
disruptive technologies. 

Khosla Ventures, with a history of investing in "Black Swan" ideas that offer 
significant upside, became the newest investor in Turn, joining the Shanda 
Group and Formic Ventures. These firms have stakes in cutting-edge Asian, 
European and North American companies and are credited with investing in 
tipping point companies worldwide.

"Turn sits at the convergence of several areas of recent dramatic innovation, 
namely in delivery of RNA as a therapeutic, understanding of cellular 
senescence, and cellular reprogramming," said Alex Morgan, MD, PhD, Partner at 
Khosla Ventures. "This technology out of Stanford University is on track to 
creating novel therapeutics to help heal and rejuvenate age-damaged tissues."

Khosla, Shanda Group and Formic Ventures join Turn's early investors, 
Methuselah Fund and Methuselah Foundation, which specialize in companies 
committed to extending healthy lifespans and improving quality of life as we 
age. 

"These investments by funds with a reputation for picking winners around the 
world recognize Turn's innovation, vision and potential to disrupt the market," 
said CEO Anja Krammer. "As the population ages, millions of elderly persons are 
forced to cope with age-related conditions for which only symptomatic treatment 
exists.  Our new investors enable Turn to bring to the market the promise of a 
technology that has the potential to improve quality of life and change 
healthcare economics globally."

Turn focuses on the repair of tissue at the cellular level, utilizing its 
patent-pending mRNA platform technology, ERA™, to combat the effects of aging 
in the epigenome, thus restoring optimal gene expression and enabling cells to 
function as vigorously as younger cells. This restores the cells' ability to 
prevent or treat disease and heal or regenerate tissue. 

Use of mRNA, which led to the quick development of two COVID-19 vaccines 
approved for use in the United States, promises to revolutionize the 
development of therapeutics by making that development safer, faster, more 
efficient and extremely tunable to patient need.

Turn's epigenetic reprogramming technology has the potential to significantly 
impact a wide variety of age-related diseases, and the company is currently 
exploring treatments for dermatologic, osteoarthritic, ophthalmic and muscular 
conditions. Its work in these areas has also attracted several potential 
partners, which are currently in discussions with Turn.

ABOUT TURN BIOTECHNOLOGIES 
Turn is a pre-clinical-stage company focused on repairing tissue at the 
cellular level. The company's proprietary mRNA technology combats the effects 
of aging in the epigenome, thus restoring optimal gene expression and enabling 
cells to function as vigorously as when they were younger. Turn's technology 
provides a platform from which to attack a variety of diseases related to age. 
The company is currently completing pre-clinical research on tailored therapies 
targeting indications in dermatology, ophthalmology, osteo-arthritis and 
cartilage damage and musculature. For more information, see www.turn.bio.

ABOUT KHOSLA VENTURES 
Khosla Ventures provides venture assistance and strategic advice to 
entrepreneurs working on breakthrough technologies. The firm was founded by 
Vinod Khosla, co-founder of Sun Microsystems, and focuses on transformative 
technology in consumer, enterprise, education, financial services, health, big 
data, agriculture/food, sustainable energy and robotics. For more information, 
see www.khoslaventures.com.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup
jim@rightstorygroup.com or +1 (312) 543-9026

or 

Wendy Dolwig, Turn Biotechnologies
wendy.dolwig@turn.bio 
 

SOURCE: Turn Biotechnologies, Inc.